{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36030292",
  "DateCompleted": {
    "Year": "2022",
    "Month": "08",
    "Day": "30"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "09",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "08",
        "Day": "27"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "247",
      "10.1186/s12936-022-04261-z"
    ],
    "Journal": {
      "ISSN": "1475-2875",
      "JournalIssue": {
        "Volume": "21",
        "Issue": "1",
        "PubDate": {
          "Year": "2022",
          "Month": "Aug",
          "Day": "27"
        }
      },
      "Title": "Malaria journal",
      "ISOAbbreviation": "Malar J"
    },
    "ArticleTitle": "Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites.",
    "Pagination": {
      "StartPage": "247",
      "MedlinePgn": "247"
    },
    "Abstract": {
      "AbstractText": [
        "Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines are the only candidate malaria vaccines that induce\u2009>\u200990% vaccine efficacy (VE) against controlled human malaria infection and the only malaria vaccines to have achieved reproducible VE against malaria in adults in Africa. The goal is to increase the impact and reduce the cost of PfSPZ vaccines by optimizing vaccine potency and manufacturing, which will benefit from identification of immunological responses contributing to protection in humans. Currently, there is no authentic animal challenge model for assessing P. falciparum malaria VE. Alternatively, Plasmodium knowlesi (Pk), which infects humans and non-human primates (NHPs) in nature, can be used to experimentally infect rhesus macaques (Macaca mulatta) to assess VE.",
        "Sanaria has, therefore, produced purified, vialed, cryopreserved PkSPZ and conducted challenge studies in several na\u00efve NHP cohorts. In the first cohort, groups of three rhesus macaques each received doses of 5\u2009\u00d7\u200910<sup>2</sup>, 2.5\u2009\u00d7\u200910<sup>3</sup>, 1.25\u2009\u00d7\u200910<sup>4</sup> and 2.5\u2009\u00d7\u200910<sup>4</sup> PkSPZ administered by direct venous inoculation. The infectivity of 1.5\u2009\u00d7\u200910<sup>3</sup>\u00a0PkSPZ cryopreserved with an altered method and of 1.5\u2009\u00d7\u200910<sup>3</sup>\u00a0PkSPZ cryopreserved for\u00a0four years was tested in a second and third cohort of rhesus\u00a0NHPs. The lastly, three pig-tailed macaques (Macaca nemestrina), a natural P. knowlesi host, were challenged with 2.5\u2009\u00d7\u200910<sup>3</sup> PkSPZ\u00a0cryopreserved six years earlier.",
        "In the first cohort, all 12 animals developed P. knowlesi parasitaemia\u00a0by thick blood smear, and the time to positivity (prepatent period) followed a non-linear 4-parameter logistic sigmoidal model with a median of 11, 10, 8, and 7 days, respectively (r<sup>2</sup>\u2009=\u20091). PkSPZ cryopreserved using a modified rapid-scalable method infected rhesus with a pre-patent period of 10 days, as did PkSPZ cryopreserved four years prior to infection, similar to the control group. Cryopreserved PkSPZ infected pig-tailed macaques with median time to positivity by thin smear, of 11 days.",
        "This study establishes the capacity to consistently infect NHPs with purified, vialed, cryopreserved PkSPZ, providing a foundation for future studies to probe protective immunological mechanisms elicited by PfSPZ vaccines that cannot be established in humans."
      ],
      "CopyrightInformation": "\u00a9 2022. The Author(s)."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sanaria, Inc, 9800 Medical Center Drive, Suite A209, Rockville, MD, 20850, USA."
          }
        ],
        "LastName": "Chakravarty",
        "ForeName": "Sumana",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Washington National Primate Research Center, University of Washington, Seattle, WA, USA."
          }
        ],
        "LastName": "Shears",
        "ForeName": "Melanie J",
        "Initials": "MJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sanaria, Inc, 9800 Medical Center Drive, Suite A209, Rockville, MD, 20850, USA."
          }
        ],
        "LastName": "James",
        "ForeName": "Eric R",
        "Initials": "ER"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sanaria, Inc, 9800 Medical Center Drive, Suite A209, Rockville, MD, 20850, USA."
          }
        ],
        "LastName": "Rai",
        "ForeName": "Urvashi",
        "Initials": "U"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sanaria, Inc, 9800 Medical Center Drive, Suite A209, Rockville, MD, 20850, USA."
          }
        ],
        "LastName": "Kc",
        "ForeName": "Natasha",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Malaria Immunology and Vaccinology, NIAID/NIH, Bethesda, USA."
          }
        ],
        "LastName": "Conteh",
        "ForeName": "Solomon",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Malaria Immunology and Vaccinology, NIAID/NIH, Bethesda, USA."
          }
        ],
        "LastName": "Lambert",
        "ForeName": "Lynn E",
        "Initials": "LE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Malaria Immunology and Vaccinology, NIAID/NIH, Bethesda, USA."
          }
        ],
        "LastName": "Duffy",
        "ForeName": "Patrick E",
        "Initials": "PE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Washington National Primate Research Center, University of Washington, Seattle, WA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology, University of Washington, Seattle, WA, USA."
          }
        ],
        "LastName": "Murphy",
        "ForeName": "Sean C",
        "Initials": "SC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sanaria, Inc, 9800 Medical Center Drive, Suite A209, Rockville, MD, 20850, USA. slhoffman@sanaria.com."
          }
        ],
        "LastName": "Hoffman",
        "ForeName": "Stephen L",
        "Initials": "SL"
      }
    ],
    "GrantList": [
      {
        "GrantID": "P51 OD010425",
        "Acronym": "OD",
        "Agency": "NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AI141857",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "P51OD010425 (WaNPRC)",
        "Agency": "University of Washington Primate Research Center",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Malar J",
    "NlmUniqueID": "101139802",
    "ISSNLinking": "1475-2875"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Malaria Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Macaca mulatta"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Malaria"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Malaria Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Malaria, Falciparum"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Plasmodium falciparum"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Plasmodium knowlesi"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sporozoites"
    }
  ],
  "CoiStatement": "S.C., E.R.J., U.R., N.K.C., and S.L.H. are employees of Sanaria Inc, and draw their salaries from the company."
}